Cell Analysis Global Market estimated to be worth $47 billion by 2023

Boston, MA -- (ReleaseWire) -- 02/06/2017 -- Cell Analysis is a wide term that can be correlated with a range of different technologies depending on the experimental needs, from instruments to perform cellular imaging to systems that help automate specific assays. This process enables to analyse cell signaling mechanisms, elucidate molecular function, study cell behavior, and correlate multiple events with cell morphology. Live cell imaging, single cell analysis, and high content screening (HCS) are some of the few technological processes gaining more focus in the recent times. Single-cell analysis is a rapidly evolving field which analyzes individual cells for assessment of changing cell behavior and function over time during its natural states or when perturbed by external factors. Single cell analysis is picking up a good position in cell analysis market share because of its extensive application in cell research.

As estimated by IQ4I Research, Cell Analysis global market is expected to grow at a high CAGR to reach $47,088 million by 2023. The booming healthcare technology market with demand for innovative technology with early and accurate diagnosis of infectious diseases, increasing government and corporate funding, high investment in cell- based research, availability of reagents and advanced cell analysis instruments, higher demand from end users such as diagnostic laboratories for cell analysis products are some of the factors driving the cell analysis market growth. Emerging Asia Pacific cell analysis market, HCS services by various service providers and automation in oncology research for early diagnosis and cost-effective treatment are few oppurtunities for the cell analysis market. However, stringent government regulations and patent related issues, lack of skilled personnel to perform advanced cell analysis techniques, and the high cost of some of the commercial instruments are expected to hamper the market growth.

The cell analysis market is mainly segmented by techniques, products, applications, end-users and by geography. The cell analysis global market by the technique is segmented into molecular approaches and image-based approaches. The molecular approach accounted for the largest share in 2016 and the image-based approach is expected to grow at a strong CAGR from 2016-2023. Among the various types of molecular approaches, PCR accounted for largest revenue in 2016. But it is expected that the sequencing techniques has been gaining huge momentum with strong from 2016-2023. Oxford Nanopore, one of the key players in NGS technology, has recently launched a pocket NGS system MinION which has successfully sequenced a number of human samples. The company has raised 127 million of fundraising, for commercial activities and expansion in Asian countries. Among image based approaches, Cytometry generated the largest revenue in 2016 due to various technological advancements in the instruments and launch of various supporting software. The FISH technique is expected to grow at a strong CAGR from 2016-2023 due to its ability to study many cell features simultaneously in complex biology systems. Many companies have been working intensively to strengthen their market presence in this segment by launching new products. For instance, in September 2016, Agilent Technologies Inc. launched a new CE-IVD labeled IQFISH lung cancer panel for automated analysis.

The cell analysis global market is segmented based on techniques, products, applications, and end-users. The market by techniques is divided into Molecular based approaches and image based approaches; based on products into consumables, instruments, software, services and based on application into by process, by field and by therapeutic area

Based on process of application is segmented into cellular processes, signal transduction pathways, circulating tumor cells, single cell analysis, epigenetic target analysis, subpopulation characterization, drug and candidate screening. By field is further segmented into forensic, therapeutics, cell imaging, biomarker research, genomic analysis, stem cell analysis, and diagnostics. By therapeutics is further segmented into cancer research, infectious disease diagnosis, genetic testing, immunology, and others.

The End-users consists hospitals, academic and research institutes, contract research organizations (CROs), pharmaceuticals and biotechnology companies, cell banks, diagnostic laboratories and others. The academics and research institutes contributed the largest revenue as per estimates of IQ4I Research.

The cell analysis global market by geography is divided into North America, Europe, Asia-Pacific and Rest of the World (RoW). North America commanded the largest market share in 2016 due to high investments in healthcare infrastructures, availability of government funds improved market growth in this region. However, Asia-pacific region is expected to grow at the highest CAGR due to increased healthcare awareness, improved economic growth, and increasing disposable incomes

The major players in the cell analysis global market are Agilent Technologies, Inc. (U.S.), Becton Dickinson and Company (U.S.), Bio-Rad Laboratories (U.S.), Danaher Corporation (U.S.), GE Healthcare (U.K.), Merck KGaA (Germany), Olympus Corporation (Japan), PerkinElmer, Inc. (U.S.), Promega Corporation (U.S.), Qiagen N.V. (Netherlands), and ThermoFisher Scientific, Inc. (U.S.).

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Spine implants are used for treating of spine disorders that develop due to ageing and injury. Prevalence of spine diseases, technological advancement, and adoption of MIS are driving market growth.

Bangalore, Karnataka -- (ReleaseWire) -- 01/11/2017 -- This report analyzes the spine implants global market in terms of market revenue ($ million) for all segments and it enables spine implant manufacturers, product distributors and wholesalers, hospitals, original equipment manufacturers & group purchasing organizations to identify and analyze market expansion opportunities, upcoming technologies, Patent Trends and competition in spine implants global market.

Spine implant devices are used for the treatment of congenital spine disorders and disorders of the spine that develop due to ageing and injury. Prevalence of spine diseases and disorders due to the ageing population, technological advancement and growing healthcare expenditure and demand for minimally invasive surgery are driving market growth. However, strict regulatory requirements with the high cost of device development, lack of patient awareness and primary healthcare infrastructure in developing countries, high cost associated with the device and procedure are hindering the growth of the market. The lack of properly trained professional who could use the advanced surgical instruments is severely affecting the development of the market. According to World Health Organization (WHO), the global population of over 60 years is estimated to increase from 12% of the overall population in 2015 to about 22% by 2050 increasing the number of people with some form of spinal disorders. This projected increase in the old aged patient population provides an opportunity for medical devices companies to come up with effective implants and treatment techniques.

Spine surgery is commonly performed as open surgery with a long incision in the operative site to view and access the spinal anatomy. Since, open spine surgery results in considerable amount of trauma and requires long recovery periods; minimally invasive spine surgery is preferred over open surgery. Minimally invasive technology which offers advantage such as less trauma, cost effectiveness and quick post-operative recovery period has emerged as front runner in spine disease treatment. The types of surgery performed on spine are fusion, nonfusion and vertebral compression fracture (VCF) surgery and all these surgery includes use of biologics.

Spinal fusion is a surgical implant procedure where two or more spinal vertebrae are fused together to restrict movement and provide stability to the spine. The disadvantages such as Pseudarthrosis, restricted movement, loss of proper spinal curvature can be overcome by non-fusion spine implants. Non-fusion implants have become exciting areas in today's spine surgery world, as these implants can be implanted in order to treat various spine conditions. Non-fusion implants have increased the level of preservation in terms of movement and enhanced flexibility which is considered to be lost in fusion techniques/procedures. The major advantages of non-fusion devices over fusion devices are spinal flexibility, elimination of pseudoarthrosis, reduction of adjacent level degeneration.

The spine implant devices global market is segmented into fusion, non-fusion, VCF and biologics implants based on the type. The fusion devices market is sub segmented into Interbody fusion devices, Plate fixation systems, and screw and rod fixation systems. The non-fusion devices are classified into dynamic stabilisation systems, artificial disc implants, nucleus replacement and annulus repair. The vertebral compression fracture (VFC) is segmented into Vertebroplasty and Kyphoplasty. While, that of biologics are classified into Spinal Bone grafts, Spinal Bone graft substitutes, and Bone stimulators. Hospitals, consisting of public funded and private for profit are the end-users. Among these, public hospital accounts for largest share and is growing strongly at a CAGR of 6.6%.

The spine implant devices global market based on geography is divided into North America, Europe, Asia-Pacific and Rest of the world. North American region commanded the largest revenue market by growing at a CAGR of 6.6%. Favourable reimbursement coverage and high investments in healthcare infrastructures have led the market growth in this region. However, Asia- Pacific region is expected to grow at the highest CAGR of 8.2% from 2015 to 2022 due to increased healthcare awareness, improved economic growth and increasing government funds, increasing trends of medical tourism, large patient pool and rising aged population with increased surgeries.

Stryker, Medtronic, Nuvasive, Depuy Synthes, Globus Medical, B.Braun, Zimmer-Biomet, Orthofix, K2M, Alphatec spine, LDR Holdings, and Exatech are some of the companies that play a major role in manufacturing spine implant devices. Medtronic accounts for the major spine implant market share followed by DePuy Synthes (J&J) and Nuvasive.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Cell Analysis Global Market estimated to be worth $47 billion by 2023

Boston, MA -- (SBWIRE) -- 01/09/2017 -- Cell Analysis is term that is correlated with a range of different technologies from instruments to perform cellular imaging to systems that help automate specific assays enabling analysis of cell signaling mechanisms, elucidate molecular function, study cell behavior, and correlate multiple events with cell morphology. Live cell imaging, single cell analysis, and high content screening (HCS) are some of the few technological processes gaining more focus in the recent times. Single-cell analysis is a rapidly evolving field which analyzes individual cells for assessment of changing cell behavior and function over time during its natural states or when perturbed by external factors.

As estimated by IQ4I Research, Cell Analysis global market is expected to grow at a high CAGR to reach $47,088 million by 2023. The booming healthcare technology market with demand for innovative technology with early and accurate diagnosis of infectious diseases, increasing government and corporate funding, high investment in cell- based research, availability of reagents and advanced cell analysis instruments, higher demand from end users such as diagnostic laboratories for cell analysis products are some of the factors driving the cell analysis market growth.

The cell analysis market is mainly segmented by techniques, products, applications, end-users and by geography. The cell analysis global market by the technique is segmented into molecular approaches and image-based approaches. The molecular approach accounted for the largest share, the image-based approach is expected to grow at a strong CAGR from 2016-2023.

The market by techniques is divided into Molecular based approaches and image based approaches; based on products into consumables, instruments, software, services and based on application into by process, by field and by therapeutic area, based on process of application is segmented into cellular processes, signal transduction pathways, circulating tumor cells, single cell analysis, epigenetic target analysis, subpopulation characterization, drug and candidate screening. By field is further segmented into forensic, therapeutics, cell imaging, biomarker research, genomic analysis, stem cell analysis, and diagnostics. By therapeutics is further segmented into cancer research, infectious disease diagnosis, genetic testing, immunology, and others.

The End-users consists hospitals, academic and research institutes, contract research organizations (CROs), pharmaceuticals and biotechnology companies, cell banks, diagnostic laboratories and others. The academics and research institutes contributed the largest revenue as per estimates of IQ4I Research.

The cell analysis global market by geography is divided into North America, Europe, Asia-Pacific and Rest of the World (RoW). North America commanded the largest market share in 2016. Asia-pacific region is expected to grow at the highest CAGR due to increased healthcare awareness, improved economic growth, and increasing disposable incomes

The major players in the cell analysis global market are Agilent Technologies, Inc. (U.S.), Becton Dickinson and Company (U.S.), Bio-Rad Laboratories (U.S.), Danaher Corporation (U.S.), GE Healthcare (U.K.), Merck KGaA (Germany), Olympus Corporation (Japan), PerkinElmer, Inc. (U.S.), Promega Corporation (U.S.), Qiagen N.V. (Netherlands), and ThermoFisher Scientific, Inc. (U.S.).

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Aortic Aneurysm Repair Devices Global Market estimated to be worth $3,448.2 million by 2023

Boston, MA -- (SBWIRE) -- 01/09/2017 -- An aortic aneurysm refers to an enlargement (or dilation) of the aorta to greater than 1.5 times normal size. Aortic aneurysm symptoms often do not show up until an aneurysm becomes large or bursts and cause bleeding or even death. But as it grows, some signs including, chest or back pain, difficulty breathing or swallowing, shortness of breath, coughing, hoarseness can be noticed. Other causes for an aneurysm may include, high blood pressure, infection, plaque build-up in arteries (atherosclerosis), smoking, high cholesterol and sudden traumatic injury. Based on the location, an aortic aneurysm is classified into two type's Abdominal Aortic Aneurysm (AAA)and Thoracic Aortic Aneurysm (TAA). According to IQ4I analysis, the Aortic Aneurysm repair devices global market is expected to grow at a mid single digit CAGR from 2016-2023.

Rising geriatric population, increasing the number of lifestyle diseases, growing acceptance for minimally invasive endovascular surgeries and technological advancements in EVAR are expected to propel the growth of Aortic Aneurysm Repair Devices global market. However, some issues like risks associated with endovascular procedures such as endoleaks, radiation exposure and high costs of endovascular aneurysm repair procedures may hinder the growth of Aortic Aneurysm repair devices market.

The Aortic Aneurysm Repair Devices global market by site is segmented into Abdominal Aortic Aneurysm (Infrarenal and Perarenal)and Thoracic Aortic Aneurysm (Ascending, Descending, Thoracoabdominal and Aortic Arch). The Abdominal Aortic Aneurysm contributed the largest revenue in 2016 as per estimates of IQ4I Research. Thoracic Aortic Aneurysm is expected to grow at the highest CAGR by 2023. The Aortic Aneurysm Repair Devices global market by products is segmented into Stent grafts, Catheters and Others. The stents grafts occupied highest market in 2016 of Aortic Aneurysm Repair Devices product market.

The Aortic Aneurysm Repair Devices global market by Repair Type is segmented into Abdominal Aortic Aneurysm and Thoracic Aortic Aneurysm. Abdominal Aortic Aneurysm is segmented into Open surgery repair and Endovascular aortic repair (EVAR). The endovascular aneurysm repair occupied largest market share in Abdominal Aortic Aneurysm Repair Devices by repair type market and is expected to grow at a high CAGR. Thoracic Aortic Aneurysm by repair type is segmented into Open surgery and Thoracic endovascular aneurysm repair (TEVAR). The Thoracic endovascular aneurysm repair contributed the largest revenue and is expected to grow at a high CAGR as per estimates of IQ4I Research. The Aortic Aneurysm Repair Devices global market based on geography is divided into North America, Europe, Asia-Pacific and Rest of the world. North American region commanded the largest revenue in 2016. Asia-pacific region is expected to grow at the highest CAGR.

Some of the prominent players in aortic aneurysm repair devices market include Bolton Medical (U.S.), Cook Medical (U.S.), Endologix, Inc. (U.S.), Lombard Medical Technologies (U.K.), Medtronic plc (Ireland), MicroPort Scientific Corporation (China),Terumo Medical Corporation (Japan), W.L. Gore and Associates, Inc. (U.S). Some of the emerging players are JOTEC GmbH (Germany), LifeTech Scientific Inc. (China), Endospan (Israel), Nano Endoluminal S.A. (Brazil), Braile Biomedica (Brazil) etc.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm